Clinical Trial Update: Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for cabozantinib-s-malate in recurrent or progressive ovarian, fallopian tube, or primary peritoneal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Carcinoma
• Fallopian Tube Clear Cell Adenocarcinoma
• Ovarian Carcinoma
• Ovarian Clear Cell Adenocarcinoma
• Peritoneal Carcinoma

Drugs mentioned

• Cabozantinib S-Malate (cabozantinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Fallopian Tube Clear Cell Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-03-10